Advertisement
Screener

Aptevo Therapeutics Inc. (APVO) Unamortized Debt Issuance Expense

2.8 / 5 stars · 68/120 Roast Me

Aptevo Therapeutics Inc. Unamortized Debt Issuance Expense

Aptevo Therapeutics Inc. (APVO) had Unamortized Debt Issuance Expense of $1.40 million as of 2017-12-31, per its 10-K filed 2018-03-13.

Discontinued › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:UnamortizedDebtIssuanceExpense · last filed 2018-03-13

  • 2017-12-31: Unamortized Debt Issuance Expense $1.40M.
  • 2017-09-30: Unamortized Debt Issuance Expense $1.50M.
  • 2017-06-30: Unamortized Debt Issuance Expense $1.50M.
  • 2017-03-31: Unamortized Debt Issuance Expense $1.60M.
Period endUnamortized Debt Issuance Expense
2017-12-31$1.40M
10-K · filed 2018-03-13
2017-09-30$1.50M
10-Q · filed 2017-11-13
2017-06-30$1.50M
10-Q · filed 2017-08-10
2017-03-31$1.60M
10-Q · filed 2017-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Onconetix, Inc. (ONCO)United States$0.004B
Sunshine Biopharma Inc. (SBFM)$0.003B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B